View Clinical Data
Cellular Bioenergetics

Controlled mitochondrial uncoupling therapies

Our clinical-stage therapeutic platform utilizes controlled mitochondrial uncoupling to address cellular energy regulation, offering disease-modifying potential for MASH and obesity.

Phase 2

Clinical Pipeline

Preserved

Lean Muscle Mass

Macro photograph of a high-tech laboratory perfusion system, bright cool ambient blue and white lighting, sharp focus on glass chambers and microfluidic tubes, professional depth of field
Macro photograph of a high-tech laboratory perfusion system, bright cool ambient blue and white lighting, sharp focus on glass chambers and microfluidic tubes, professional depth of field
Mechanism of Action

Accelerating lipid clearance

Unlike traditional appetite suppressants, our approach safely accelerates natural metabolic processes. By regulating cellular energy expenditure, HU6 clears excess lipids and systemic fat while actively preserving lean muscle tissue.

This physiological shift targets the root cause of metabolic dysfunction, providing clinical-stage data that points toward a new paradigm in cardiometabolic health.

Clinical Efficacy

Phase 2a clinical data

Our lead candidate, HU6, demonstrated significant reduction in liver fat and systemic lipids during controlled trials, validating our bioenergetic approach.

60%

Reduction in liver fat

Zero

Lean muscle mass loss

Phase 2b

Currently in active trials

Scientific Rigor

Peer-reviewed publications

Our scientific foundation is built on rigorous, published research in leading medical journals, translating complex cellular bioenergetics into validated therapeutic pathways.

The Lancet
Nature Metabolism
Cardiovascular Research

Mitochondrial Uncoupling in MASH

Preserving Lean Muscle Tissue

Cardiometabolic Risk Reduction

A comprehensive review of controlled uncoupling agents and their therapeutic efficacy in reducing hepatic steatosis.

Clinical analysis demonstrating how cellular energy regulation bypasses muscle wasting associated with GLP-1 therapies.

Investigating the systemic benefits of controlled metabolic acceleration on lipid profiles and vascular health.